VRCA

Verrica Pharmaceuticals

VRCA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,520

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.73

Market capitalization79M

Earnings per share-1.74

Dividend yield (TTM)—

Revenue (annual)35.6M

Net income (annual)-17.9M

Social

What share of all stock conversation is about VRCA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 4

Verrica Pharmaceuticals' stock has been increasing strongly with recent insider buying.
A user is surprised by the lack of discussion about Verrica Pharmaceuticals despite insider activity and stock price increase.
A shareholder is unhappy about the company's stock split, with an average price of $40, and hopes for a reverse stock split.

Generated by AI

Sentiment

Of the messages about VRCA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.07% +5.6
Bearish	—	—	—	9.93% -5.6

Bullish· Nov 29

VRCA's forecast is expected to reach $100M+ next year, making its current valuation extremely low.
The stock experienced a significant price surge, with a 25% increase in a single day and a massive volume spike of over 20x average volume.
VRCA's price volatility is expected to continue, with a smart move being to wait for the stock's heat percentage (H%) to cool down before considering an entry.

Bearish· Dec 15

$VRCA has been rejected at $5.50 multiple times, suggesting it may need a significant push to break through.
The stock's short interest is high, with 18% of its float being short, which could lead to a squeeze and significant losses for short sellers.
$VRCA has broken its support levels, with the latest move being described as a "flush" and the bears being given confidence to add to their positions.

Generated by AI

Topics

Of the messages about VRCA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	59.02%
Analysts	—	—	0%	12.14%
Controversies	—	—	0%	0%
Earnings	—	—	0%	2.02%
Macro	—	—	0%	7.76%
Technical Analysis	—	—	0%	19.06%

Announcements· Sep 19

Verrica Pharmaceuticals' development partner, Torii Pharmaceutical, received approval for YCANTH (TO-208) in Japan to treat molluscum contagiosum.
The approval triggers a $10 million cash milestone payment to Verrica, providing non-dilutive capital to support its U.S. commercial launch of YCANTH.
Verrica retains global rights to YCANTH outside Japan and is collaborating with Torii on a global Phase 3 program to study the therapy for common warts.

Controversies· Jun 18

VRCA Stock has experienced a 72% loss, with some investors expressing concern and seeking further information.
Three law firms have issued press releases reminding investors of class action lawsuits against Verrica Pharmaceuticals Inc. (VRCA) with looming deadlines.
There are ongoing class actions and securities lawsuits against Verrica Pharmaceuticals Inc. (VRCA) regarding significant losses in the company's stock.

Technical Analysis· Dec 15

$VRCA has a 70% win rate with a specific trading pattern that occurs 4-5 times a week.
The stock's bulls are in control, with a 36.6% gain and a short interest of 17.0%, and a VWAP crossover indicating a strong upward momentum.
$VRCA's bulls remain trapped, with a decision time approaching, and a pivotal squeeze zone at $6.92, while shorts are trapped unless the stock moves over $5.6.

Generated by AI

Community

Of the messages about VRCA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	65.88%
Newcomers	—	—	100%	34.12%

Regulars· Dec 15

Verrica Pharmaceuticals' partner, Torii Pharmaceutical, reported positive Phase 3 trial results for its treatment of molluscum contagiosum in Japan, which contributed to the company's stock price rising 12%.
Jefferies maintains a "Buy" rating for Verrica Pharmaceuticals with a price target of $10.
The company's stock price surged more than 51% since the last post, with the complete float of 17.9M shares being traded in a single day, and the traded volume reaching 18.0M shares.

Newcomers· Nov 28

Newcomers are focusing on the stock's recent price increase of 28.46% due to insider buying and a $50 million funding round.
The low float of 3.83M and low market cap of $81M are being highlighted as potential factors to consider when evaluating the stock.
Insider buying is being viewed as a bullish signal, with executives purchasing shares and driving the stock price up, despite some retail traders expressing concerns about the company's offerings.

Generated by AI

Also Discussed

Investors talking about VRCA also mention

#	Name	Attention
1	Mirum Pharmaceuticals, Inc.MIRM	0%0
2	Arcutis Biotherapeutics, Inc.ARQT	0%+0
3	Eton Pharmaceuticals, Inc.ETON	0%-0.01
4	C4 Therapeutics IncCCCC	0.01%new
5	AVDL - Avadel Pharmaceuticals plc	——
6	Shattuck Labs, Inc.STTK	0%new
7	Surrozen, Inc.SRZN	0%0
8	Syros Pharmaceuticals Inc.SYRS	0%0
9	LABP - Landos Biopharma, Inc.	——
10	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91

Verrica Pharmaceuticals Inc.

Healthcare
Biotechnology

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and commercializing medications for the treatment of skin diseases in the United States. The company's primary product is YCANTH (VP-102), a drug-device combination featuring a topical cantharidin solution with a precision applicator designed for treating molluscum contagiosum and common warts in both adult and pediatric patients. The product has received regulatory approval in Japan and is advancing through phase III clinical trials for additional indications. Verrica also develops VP-315, an oncolytic peptide-based injectable therapy currently in phase II trials for dermatologic oncology conditions, including basal cell carcinoma. The company generates revenue through direct product sales and collaboration agreements with international partners. Headquartered in West Chester, Pennsylvania, Verrica operates with a focused pipeline addressing significant unmet needs in viral and oncologic skin diseases, positioning itself as an innovative player in the specialized dermatology therapeutics market.

Website

Location

44 West Gay Street

West Chester, PA, 19380

United States

Social

What share of all stock conversation is about VRCA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 4

Verrica Pharmaceuticals' stock has been increasing strongly with recent insider buying.
A user is surprised by the lack of discussion about Verrica Pharmaceuticals despite insider activity and stock price increase.
A shareholder is unhappy about the company's stock split, with an average price of $40, and hopes for a reverse stock split.

Generated by AI

Sentiment

Of the messages about VRCA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.07% +5.6
Bearish	—	—	—	9.93% -5.6

Bullish· Nov 29

VRCA's forecast is expected to reach $100M+ next year, making its current valuation extremely low.
The stock experienced a significant price surge, with a 25% increase in a single day and a massive volume spike of over 20x average volume.
VRCA's price volatility is expected to continue, with a smart move being to wait for the stock's heat percentage (H%) to cool down before considering an entry.

Bearish· Dec 15

$VRCA has been rejected at $5.50 multiple times, suggesting it may need a significant push to break through.
The stock's short interest is high, with 18% of its float being short, which could lead to a squeeze and significant losses for short sellers.
$VRCA has broken its support levels, with the latest move being described as a "flush" and the bears being given confidence to add to their positions.

Generated by AI

Topics

Of the messages about VRCA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	59.02%
Analysts	—	—	0%	12.14%
Controversies	—	—	0%	0%
Earnings	—	—	0%	2.02%
Macro	—	—	0%	7.76%
Technical Analysis	—	—	0%	19.06%

Announcements· Sep 19

Verrica Pharmaceuticals' development partner, Torii Pharmaceutical, received approval for YCANTH (TO-208) in Japan to treat molluscum contagiosum.
The approval triggers a $10 million cash milestone payment to Verrica, providing non-dilutive capital to support its U.S. commercial launch of YCANTH.
Verrica retains global rights to YCANTH outside Japan and is collaborating with Torii on a global Phase 3 program to study the therapy for common warts.

Controversies· Jun 18

VRCA Stock has experienced a 72% loss, with some investors expressing concern and seeking further information.
Three law firms have issued press releases reminding investors of class action lawsuits against Verrica Pharmaceuticals Inc. (VRCA) with looming deadlines.
There are ongoing class actions and securities lawsuits against Verrica Pharmaceuticals Inc. (VRCA) regarding significant losses in the company's stock.

Technical Analysis· Dec 15

$VRCA has a 70% win rate with a specific trading pattern that occurs 4-5 times a week.
The stock's bulls are in control, with a 36.6% gain and a short interest of 17.0%, and a VWAP crossover indicating a strong upward momentum.
$VRCA's bulls remain trapped, with a decision time approaching, and a pivotal squeeze zone at $6.92, while shorts are trapped unless the stock moves over $5.6.

Generated by AI

Community

Of the messages about VRCA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	65.88%
Newcomers	—	—	100%	34.12%

Regulars· Dec 15

Verrica Pharmaceuticals' partner, Torii Pharmaceutical, reported positive Phase 3 trial results for its treatment of molluscum contagiosum in Japan, which contributed to the company's stock price rising 12%.
Jefferies maintains a "Buy" rating for Verrica Pharmaceuticals with a price target of $10.
The company's stock price surged more than 51% since the last post, with the complete float of 17.9M shares being traded in a single day, and the traded volume reaching 18.0M shares.

Newcomers· Nov 28

Newcomers are focusing on the stock's recent price increase of 28.46% due to insider buying and a $50 million funding round.
The low float of 3.83M and low market cap of $81M are being highlighted as potential factors to consider when evaluating the stock.
Insider buying is being viewed as a bullish signal, with executives purchasing shares and driving the stock price up, despite some retail traders expressing concerns about the company's offerings.

Generated by AI

Verrica Pharmaceuticals

Social

Dec 4

Sentiment

Bullish· Nov 29

Bearish· Dec 15

Topics

Announcements· Sep 19

Controversies· Jun 18

Technical Analysis· Dec 15

Community

Regulars· Dec 15

Newcomers· Nov 28

Also Discussed

Verrica Pharmaceuticals Inc.

Company Information

Location

Also Discussed

Social

Dec 4

Sentiment

Bullish· Nov 29

Bearish· Dec 15

Topics

Announcements· Sep 19

Controversies· Jun 18

Technical Analysis· Dec 15

Community

Regulars· Dec 15

Newcomers· Nov 28